Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves APP's Abraxane Paclitaxel Formulation

This article was originally published in The Pink Sheet Daily

Executive Summary

American Pharmaceutical Partners will submit survival data and pharmacokinetic data in subjects with hepatic impairment for Abraxane as part of the company's Phase IV commitments. APP hopes to position Abraxane as safer and more effective than Bristol's Taxol and paclitaxel generics.
Advertisement

Related Content

Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Abraxane vs. Taxotere: Abraxis Prepares To Go Head-To-Head In Phase III Trials
Abraxane vs. Taxotere: Abraxis Prepares To Go Head-To-Head In Phase III Trials
Abraxis Splits Injectable Generics Business Into Separate Unit
Oncology Panel To Determine Whether Abraxane Needs Randomized Trial In Adjuvant Breast Cancer
AstraZeneca To Co-Promote Abraxis’ Paclitaxel
Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere
Abraxane Reps Will Number 100: Approval Of Novel Paclitaxel Formulation Expected In Third Quarter
Abraxane Reps Will Number 100: Approval Of Novel Paclitaxel Formulation Expected In Third Quarter

Topics

Advertisement
UsernamePublicRestriction

Register

PS061059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel